Generation Bio Co

GBIO

Company Profile

  • Business description

    Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

  • Contact

    301 Binney Street
    CambridgeMA02142
    USA

    T: +1 617 655-7500

    https://www.generationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    115

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.702.300.03%
CAC 407,715.428.05-0.10%
DAX 4024,145.3271.650.30%
Dow JONES (US)44,406.36422.17-0.94%
FTSE 1008,821.7115.180.17%
HKSE24,148.07260.241.09%
NASDAQ20,412.52188.59-0.92%
Nikkei 22539,688.81101.130.26%
NZX 50 Index12,859.0294.070.74%
S&P 5006,229.9849.37-0.79%
S&P/ASX 2008,590.701.400.02%
SSE Composite Index3,497.4824.350.70%

Market Movers